Money
7 items from the daily postsFunding rounds, valuations, acquisitions and the earnings calls that mention physician labor. Each item links to the day it ran and to its original source.
- Money Sept 22, 2026The round is a $100 million Series C led by Blackbird with Phoenix Court, Point72 Private Investments and Headline, plus $240 million of growth financing from General Catalyst's Customer Value Fund, at a $900 million valuation, MobiHealthNews reported. The company's own figures, reported by HIT Consultant, are 2.8 million visits a week, 175 million visits supported in total, 67 million clinical hours, annual recurring revenue of $50 million by April and a 62% enterprise activation rate, all unaudited; Heidi's media page had not posted the announcement as of publication, and the figures come from the trade press. Thomas Kelly, the company's chief executive, said the ambition was "always bigger than writing doctor's notes," and the roadmap is agents that prepopulate order sets, draft referrals and assemble the pre-visit record, with the clinician approving before anything executes. SiliconANGLE listed the products already shipped, including an evidence tool the company said has answered 10 million queries since March, and named Beth Israel Lahey Health and NHS England's Midlands region as customers. This site reported Monday that Heidi's Asia-Pacific medical officer said 83% of the clinicians the company surveyed use AI with no employer policy.
- Money Sept 21, 2026The offering consists of 13.5 million shares from the company and 36.5 million from existing holders, listed on the Nasdaq under the symbol OURA, with Goldman Sachs, Morgan Stanley and J.P. Morgan leading; at the midpoint of the range the deal would total about $2.1 billion, less than the $3 billion at a valuation above $16 billion that Bloomberg reported in August. The S-1 shows 5.0 million paid members at June 30, revenue of $1.21 billion in the nine months to June 30 (hardware $974 million, membership $240 million, up 74%) and year-to-date net income of $60.8 million; Fierce Healthcare reported the member demographics, about 72% women and 27% over 45. The filing describes an AI health companion, Oura Advisor, and custom health LLMs, and states that the company markets its products as general wellness products that it believes are not subject to FDA device rules. The filing does not mention Counsel Health, ACCESS or Medicare, although Oura members have been able to reach Counsel's physicians inside the app since Sept. 17.
- Money Sept 19, 2026The panel met Sept. 17 to 19, the last meeting of the cycle that produces the 2028 code set, with 94 tabs on the agenda: 49 Category I proposals, 40 Category III proposals and a handful of guideline changes. Seven of the 94 describe AI services, four of them seeking permanent codes: quantitative MRI software for liver tissue composition (Tab 36), augmentative arrhythmia analysis from computational cardiac simulations (Tab 46), noninvasive measurement of left ventricular end-diastolic pressure to detect heart failure (Tab 48) and electrical impedance spectroscopy of skin lesions (Tab 49). The other three seek Category III codes: augmentative algorithmic analysis of digitized prostate slides (Tab 68), augmentative breast cancer risk prediction from screening mammograms (Tab 82) and noninvasive identification of ST-elevation myocardial infarction (STEMI) and its equivalents (Tab 84). Tab 94 would rewrite the pathology and laboratory code application to ask about software and its validation, which Madhani Healthcare Consulting and the Discoveries in Health Policy blog both flagged as the AI change that will outlast any single code. The AMA's Appendix S taxonomy, updated the day the meeting opened, supplies the vocabulary: assistive software provides data, augmentative software provides a score or parameter and autonomous software makes the interpretation itself. Three of the seven proposals are labeled augmentative in the agenda, and none is labeled autonomous. The votes are not yet public; the panel publishes a summary of its actions weeks after it meets. Whether Medicare pays for any code the panel accepts would be decided in the 2028 fee schedule.
- Money Sept 18, 2026Angle Health's round, announced Sept. 18, consists of $200 million in new Series C funding and a $400 million tender that lets earlier holders sell, led by Vitruvian Partners with Town Hall Ventures joining Blumberg, Portage, PruVen and Y Combinator; the valuation has more than doubled since December. The company reported more than 5,000 employer groups in 47 states, about $1 billion in annualized premium equivalents, revenue up 120% year over year, four straight quarters of profit and median renewal increases of 5% to 7% against an 18% small-business average, all company figures. The AI operates on the payer side: algorithmic underwriting that replaces actuarial review, quoting engines that produce a plan in minutes and "automated clinical steering" for specialty drugs, home infusion and imaging. When a physician orders an MRI for a member, the plan's software rather than a person selects the site the plan prefers and the price it will pay. The $2.7 billion valuation comes as state laws and Connecticut plan rules reported this week seek to keep a person in the loop on denials; steering is not a denial.
- Money Sept 16, 2026Sword Health said in a Sept. 16 release that the deal is all cash and should close at the start of the fourth quarter; the release does not give a price, and the figure of up to $300 million comes from the trade press. Headspace was valued at $3 billion when it merged with Ginger in 2021. Sword, a virtual physical-therapy company valued at about $4 billion, said it has treated more than 1 million people with what it calls AI Care and serves 2,500 organizations; Headspace brings a 15,000-provider network, 84 peer-reviewed studies and 20,000 employer clients, according to the companies' own figures. Headspace's chief executive described the target model as one that "brings in a human clinician when it is needed." Headspace is also an accepted participant in Medicare's ACCESS behavioral health track, which pays for technology-enabled care of depression and anxiety based on outcomes.
- Money Sept 15, 2026OpenEvidence, free to clinicians and ad-supported, is valued at $12 billion; in July it considered, then shelved, a round at a $20 billion valuation. Function Health, which sells a $365-a-year lab bundle, raised another $450 million in July. Oura filed to go public in September with $1.4 billion in trailing revenue. Doximity's shares rose by roughly two-thirds after it said its AI scribe users grew tenfold. Waystar, which sells billing software, hired bankers to explore a sale after investors concluded AI would displace its business.
- Money Sept 15, 2026Waystar, a revenue-cycle software company used by hospitals and physician groups for billing and claims, has retained Evercore to run a sale process that is at an early stage and could still stall, Reuters reported. Shares are down 24% this year after a July Morgan Stanley note argued AI could disrupt software companies. EQT holds 13% of the company, CPP Investments 10% and BlackRock 8%. Waystar went public at $20 a share in 2024 and peaked at $45 in 2025. The company has said AI drives 40% of its bookings.